CRISPR Therapeutics hired Dr. Phuong Khanh Morrow as its chief medical officer. Morrow brings 10 years of experience in global drug development, including an expertise in oncology and hematology.
Previously, Morrow was VP and global therapeutic area head of hematology, GI oncology, GU oncology and bone at Amgen. Morrow also helped lead Amgen’s hematology programs including Blincyto and Kyprolis.
Prior to Amgen, Morrow served as the industry representative to the Oncology Drug Advisory Committee (ODAC) at the Food and Drug Administration (FDA).
“P.K.’s leadership experience, deep expertise in oncology drug development, and her track record in bringing novel medicines to patients will be invaluable as we continue to advance our broad portfolio of innovative gene-edited therapies,” said CRISPR CEO Samarth Kulkarni said in a statement. “She will play an integral role in shaping our clinical development strategy, and in building and strengthening our organization, and we look forward to her contributions as we continue on our mission to transform medicine.”
